Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University, #169 E Lake Rd, Wuchang District, Wuhan 430071, China.
AJR Am J Roentgenol. 2021 Dec;217(6):1433-1443. doi: 10.2214/AJR.21.25814. Epub 2021 May 12.
. Lymphovascular invasion (LVI) is an adverse prognostic indicator in non-small cell lung cancer (NSCLC) and serves as an indication for postoperative adjuvant chemotherapy recommendation after resection. . The purpose of this article was to assess the utility of clinicopathologic factors and volumetric metabolic parameters from preoperative FDG PET/CT in predicting primary tumor LVI in NSCLC. . This retrospective study included 161 patients (mean age, 61.8 ± 8.1 [SD] years; 111 men, 50 women) with surgically confirmed NSCLC who underwent preoperative FDG PET/CT between January 2018 and November 2020. Two nuclear medicine physicians used software to place automated volumes of interest delineating each tumor to record metabolic indexes (SUV, SUV, and metabolic tumor volume [MTV]), which in turn were used to calculate total lesion glycolysis (TLG). Measurements were first performed independently to determine interobserver agreement using intraclass correlation coefficients (ICCs) and then repeated in consensus. Associations of clinicopathologic and metabolic parameters with tumor LVI status were assessed using test, Mann-Whitney test, and chi-square test. Diagnostic performance was assessed using ROC analysis. Multivariable logistic regression analysis was performed to identify independent predictors of tumor LVI. . A total of 23.6% (38/161) of patients had LVI. The ICCs were 1.000 for SUV, 0.997 for SUV, and 0.999 for MTV. Tumors with LVI, compared with tumors without LVI, exhibited higher SUV (15.4 ± 5.9 vs 11.7 ± 7.5; = .006), SUV (6.0 ± 1.6 vs 5.1 ± 2.0; = .009), MTV (median, 15.8 cm vs 5.5 cm; < .001), and TLG (median, 88.8 vs 24.5; < .001). Among the metabolic parameters, AUC was highest for MTV (0.704), with an optimal MTV cutoff of 6.4 cm yielding sensitivity of 92.1% (35/38), specificity of 56.1% (69/123), PPV of 39.3% (35/89), and NPV of 95.8% (69/72) for LVI. Independent predictors ( < .05) of LVI were MTV (≥ 6.4 cm; odds ratio [OR], 6.5), category N1 (OR, 6.4) or N2 (OR, 4.0) disease, and category T2 disease (OR, 3.6). These factors combined achieved AUC of 0.854 for LVI. . The volumetric metabolic parameter MTV from preoperative FDG PET/CT is an independent predictor of tumor LVI in NSCLC. . Further studies are warranted to assess the potential role of preoperative prediction of LVI using FDG PET/CT to help guide clinical decision making in NSCLC.
. 脉管侵犯(LVI)是非小细胞肺癌(NSCLC)的不良预后指标,也是术后辅助化疗推荐的指征。. 本文旨在评估术前 FDG PET/CT 的临床病理因素和容积代谢参数在预测 NSCLC 原发性肿瘤 LVI 中的作用。. 这项回顾性研究纳入了 161 例(平均年龄 61.8 ± 8.1[SD]岁;111 例男性,50 例女性)接受手术证实的 NSCLC 患者,他们在 2018 年 1 月至 2020 年 11 月期间接受了术前 FDG PET/CT 检查。两名核医学医师使用软件自动划定每个肿瘤的兴趣区容积,以记录代谢指标(SUV、SUV 和代谢肿瘤体积[MTV]),进而计算总病灶糖酵解(TLG)。首先独立进行测量,以使用组内相关系数(ICC)确定观察者间的一致性,然后再进行共识性重复测量。使用 检验、Mann-Whitney 检验和卡方检验评估临床病理和代谢参数与肿瘤 LVI 状态的相关性。使用 ROC 分析评估诊断性能。采用多变量逻辑回归分析确定肿瘤 LVI 的独立预测因素。. 共有 23.6%(38/161)的患者存在 LVI。SUV、SUV 和 MTV 的 ICC 均为 1.000。与无 LVI 的肿瘤相比,有 LVI 的肿瘤 SUV 更高(15.4 ± 5.9 比 11.7 ± 7.5; =.006),SUV 更高(6.0 ± 1.6 比 5.1 ± 2.0; =.009),MTV 更大(中位数 15.8 cm 比 5.5 cm; <.001),TLG 更高(中位数 88.8 比 24.5; <.001)。在代谢参数中,MTV 的 AUC 最高(0.704),MTV 的最佳截断值为 6.4 cm,其 LVI 的灵敏度为 92.1%(35/38),特异性为 56.1%(69/123),PPV 为 39.3%(35/89),NPV 为 95.8%(69/72)。LVI 的独立预测因素(<.05)为 MTV(≥ 6.4 cm;比值比[OR],6.5)、N1 期(OR,6.4)或 N2 期(OR,4.0)疾病和 T2 期疾病(OR,3.6)。这些因素结合起来,LVI 的 AUC 为 0.854。. 术前 FDG PET/CT 的容积代谢参数 MTV 是 NSCLC 肿瘤 LVI 的独立预测因素。. 有必要进一步研究使用 FDG PET/CT 术前预测 LVI 的潜在作用,以帮助指导 NSCLC 的临床决策。